172 related articles for article (PubMed ID: 31004117)
1. Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro.
Majeed Y; Upadhyay R; Alhousseiny S; Taha T; Musthak A; Shaheen Y; Jameel M; Triggle CR; Ding H
Sci Rep; 2019 Apr; 9(1):6316. PubMed ID: 31004117
[TBL] [Abstract][Full Text] [Related]
2. Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1.
Wang WR; Liu EQ; Zhang JY; Li YX; Yang XF; He YH; Zhang W; Jing T; Lin R
Exp Cell Res; 2015 Oct; 338(1):54-63. PubMed ID: 26226216
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis.
Joe Y; Do MH; Seo E; Kang S; Park HT; Yun J; Lee HJ
Life Sci; 2010 May; 86(19-20):716-21. PubMed ID: 20226795
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms.
Yamasaki D; Kawabe N; Nakamura H; Tachibana K; Ishimoto K; Tanaka T; Aburatani H; Sakai J; Hamakubo T; Kodama T; Doi T
Eur J Cell Biol; 2011 Aug; 90(8):657-64. PubMed ID: 21514001
[TBL] [Abstract][Full Text] [Related]
5. Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors.
Liang H; Kowalczyk P; Junco JJ; Klug-De Santiago HL; Malik G; Wei SJ; Slaga TJ
Mol Carcinog; 2014 Sep; 53(9):753-63. PubMed ID: 23625588
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor α (PPARα) contributes to control of melanogenesis in B16 F10 melanoma cells.
Grabacka M; Wieczorek J; Michalczyk-Wetula D; Malinowski M; Wolan N; Wojcik K; Plonka PM
Arch Dermatol Res; 2017 Apr; 309(3):141-157. PubMed ID: 28084540
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Duhaney TA; Cui L; Rude MK; Lebrasseur NK; Ngoy S; De Silva DS; Siwik DA; Liao R; Sam F
Hypertension; 2007 May; 49(5):1084-94. PubMed ID: 17353509
[TBL] [Abstract][Full Text] [Related]
8. PPAR activators inhibit endothelial cell migration by targeting Akt.
Goetze S; Eilers F; Bungenstock A; Kintscher U; Stawowy P; Blaschke F; Graf K; Law RE; Fleck E; Gräfe M
Biochem Biophys Res Commun; 2002 May; 293(5):1431-7. PubMed ID: 12054675
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose.
Zanetti M; Stocca A; Dapas B; Farra R; Uxa L; Bosutti A; Barazzoni R; Bossi F; Giansante C; Tedesco F; Cattin L; Guarnieri G; Grassi G
J Mol Med (Berl); 2008 Feb; 86(2):185-95. PubMed ID: 17876565
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt.
Kubota T; Yano T; Fujisaki K; Itoh Y; Oishi R
Apoptosis; 2005 Mar; 10(2):349-58. PubMed ID: 15843896
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells.
Jeng LB; Velmurugan BK; Hsu HH; Wen SY; Shen CY; Lin CH; Lin YM; Chen RJ; Kuo WW; Huang CY
Environ Toxicol; 2018 Feb; 33(2):234-247. PubMed ID: 29134746
[TBL] [Abstract][Full Text] [Related]
12. The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin-1-induced cardiac fibroblast proliferation.
Ogata T; Miyauchi T; Irukayama-Tomobe Y; Takanashi M; Goto K; Yamaguchi I
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S279-82. PubMed ID: 15838301
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of radiosensitivity in human esophageal carcinoma cells by fenofibrate and its potential mechanism.
Li XQ; Zhou JD; Zou ST; Yu J; Meng XJ; Wu JC
Tumori; 2015; 101(1):123-30. PubMed ID: 25712601
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARα-independent pathways.
Asavapanumas N; Kittayaruksakul S; Meetam P; Muanprasat C; Chatsudthipong V; Soodvilai S
Drug Metab Pharmacokinet; 2012; 27(5):513-9. PubMed ID: 22473497
[TBL] [Abstract][Full Text] [Related]
15. Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.
Urbanska K; Pannizzo P; Grabacka M; Croul S; Del Valle L; Khalili K; Reiss K
Int J Cancer; 2008 Sep; 123(5):1015-24. PubMed ID: 18546270
[TBL] [Abstract][Full Text] [Related]
16. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.
Panigrahy D; Kaipainen A; Huang S; Butterfield CE; Barnés CM; Fannon M; Laforme AM; Chaponis DM; Folkman J; Kieran MW
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):985-90. PubMed ID: 18199835
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.
Kim J; Ahn JH; Kim JH; Yu YS; Kim HS; Ha J; Shinn SH; Oh YS
Exp Eye Res; 2007 May; 84(5):886-93. PubMed ID: 17343853
[TBL] [Abstract][Full Text] [Related]
18. PPARα agonist, fenofibrate, ameliorates age-related renal injury.
Kim EN; Lim JH; Kim MY; Kim HW; Park CW; Chang YS; Choi BS
Exp Gerontol; 2016 Aug; 81():42-50. PubMed ID: 27130813
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
Okamoto H; Iwamoto T; Kotake S; Momohara S; Yamanaka H; Kamatani N
Clin Exp Rheumatol; 2005; 23(3):323-30. PubMed ID: 15971419
[TBL] [Abstract][Full Text] [Related]
20. Nutritional background changes the hypolipidemic effects of fenofibrate in Nile tilapia (Oreochromis niloticus).
Ning LJ; He AY; Lu DL; Li JM; Qiao F; Li DL; Zhang ML; Chen LQ; Du ZY
Sci Rep; 2017 Jan; 7():41706. PubMed ID: 28139735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
